Case analysis of multiple endocrine adverse reactions associated with immune checkpoint inhibitors
10.3760/cma.j.cn311282-20220818-00494
- VernacularTitle:免疫检查点抑制剂相关的多内分泌腺体损伤的病例分析
- Author:
Ying CHEN
1
;
Hong CHEN
;
Xiaomu LI
Author Information
1. 复旦大学附属中山医院内分泌科，上海 200032
- Keywords:
Immune checkpoint inhibitor;
Immune-related adverse events;
Multiple endocrine gland damage
- From:
Chinese Journal of Endocrinology and Metabolism
2023;39(6):486-491
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features of multiple endocrine gland dysfunction in patients with tumors after using immune checkpoint inhibitors(ICIs).Methods:Cases with two or more abnormalities of endocrine gland function after immunotherapy were collected from the Department of Endocrinology, Zhongshan Hospital, Fudan University between January 2019 and January 2022. Clinical manifestations, laboratory tests, imaging, treatment and prognosis were analyzed.Results:A total of 12 patients were included, 6 males and 6 females, aged(61.2±10.0) years old. All patients received programmed cell death protein-1(PD-1) monoclonal antibody therapy, and the time to endocrine abnormality ranged from 9 to 94 weeks after administration. All patients developed primary hypothyroidism, 11 of them had isolated adrenocorticotropic hormone deficiency, and 1 had primary adrenal insufficiency.Conclusion:ICIs can involve multiple endocrine glands simultaneously or successively, mainly manifested as primary hypothyroidism and isolated adrenocorticotropic hormone deficiency. It is essential to assess the function of the pituitary and target glands in patients treated with ICIs to improve the safety of immunotherapy.
